GEN Exclusives

More »

GEN News Highlights

More »
Apr 10, 2012

DiaKine Awarded $2.1M in Grants from NIH, Iacocca Foundation for Diabetes Therapy

  • Islet Sciences’ recently acquired diabetes therapeutics subsidiary, DiaKine Therapeutics, received two separate grants totalling $2.1 million, from the NIH and Iacocca Foundation. $1,831,250 has been awarded by NIH, and another $250,000 from the Iacocca Foundation, an organization focused on funding diabetes research and drug development. 

    In January the firm acquired development-stage DiaKine is a start-up biotech developing immune modulators as treatments for diabetes and related complications. Lead candidate, Lisofylline, is a clinical development-stage compound designed to improve the function of insulin-producing islet cells and protect them from damage and premature death resulting from autoimmune attack in type 1 diabetes.

    Islet itself is focused on the development of cell transplantation therapy for treating type 1 diabetes. The firm’s initial product, Islet Sciences-P™, is a suspension of microencapsulated porcine islets designed for injection into the abdominal cavity.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?